NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity remains negative
Q1 FY2026 total equity was -$13.82M, compared with -$25.16M a year earlier.
Context
- Total equity amounted to 116.1% of total assets at the end of Q1 FY2026, down 215.4 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +45.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- (15.94M) USD
- Year-over-year change
- +31.4%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.94M) | +31.4% |
| FY2024 | 2024-12-31 | (23.22M) | -97.9% |
| FY2023 | 2023-12-31 | (11.73M) | -258.4% |
| FY2022 | 2022-12-31 | 7.41M | -64.4% |
| FY2021 | 2021-12-31 | 20.81M | — |
Total Equity vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 total equity of -$13.82M is the 7th highest of the 9 companies compared; the peer median is $19.59M.
- Its year-over-year change of +45.1% is the 5th highest of 9, against a peer median of +68.4%.
- Total equity amounts to 116.1% of total assets for NRXP, versus a peer median of 85.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $264.74M | +10.1% | -19.3% | 81.1% | |
| Mar 2026 | $59.49M | +462.4% | -3.6% | 94.3% | |
| Mar 2026 | $34.65M | +126.1% | -14.7% | 61.7% | |
| Mar 2026 | $21.61M | +228.4% | -26.2% | 70.0% | |
| Mar 2026 | $17.58M | +135.5% | +58.6% | 88.8% | |
| Jun 2026 | $16.29M | -60.7% | -41.3% | 67.4% | |
| Mar 2026 | -$13.82M | +45.1% | — | 116.1% | |
| Mar 2026 | -$28.99M | +10.7% | — | 132.4% | |
| Mar 2026 | -$265.65M | -29.0% | — | 202.1% | |
| Peer median (excluding NRXP) | $19.59M | +68.4% | -17.0% | 85.0% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.